A Lentivirus Vaccine for HIV

HIV 慢病毒疫苗

• 批准号: 6409274
• 负责人: Sybille L Sauter
• 金额: $ 26.25万
• 依托单位: CORAUTUS GENETICS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6409274
• 关键词: AIDS vaccines; Lentivirus; attenuated microorganism; cellular immunity; chemokine; cytotoxic T lymphocyte; dendritic cells; drug delivery systems; drug screening /evaluation; enzyme linked immunosorbent assay; feline immunodeficiency virus; gene expression; genetic transduction; helper T lymphocyte; humoral immunity; immunologic memory; laboratory mouse; nonhuman therapy evaluation; transfection /expression vector; vaccine development; vector vaccine; virus antigen

DESCRIPTION (Provided by applicant): Recent research has made it clear that the development of a successful HIV vaccine will depend on the choice of target antigen(s), the ability to induce appropriate immune responses to these antigens through the use of a suitable delivery system, and whether the virus is able to escape these immune responses by genetic adaptations. The induction of cellular-based immune responses, most notably CTL, to multiple and conserved viral antigens appears central to addressing these issues. Consistent with this is the observation that attenuated virus vaccination can successfully protect non-human primates. An "attenuated" HIV vaccine will be developed by incorporating a completely safe, disabled HIV immunogen (HIVgag/pol/tatnf/rev) in a non-human lentiviral system (Lenti-HIV) based on the feline immunodeficiency virus. This vaccine will not only safely mimic HIV infection, but will present a broad number of safe viral genes. Also, this vaccine will be administered via a mucosal route to optimally induce mucosal specific immune responses. This approach will allow the immune system to generate a broad cellular based immune response at the portals of HIV infection. In addition, due to the large insert capacity of lentiviral vectors, this vaccine platform offers the flexibility to include immune enhancing cytokines to ensure the development of appropriate immune responses. Studies to be conducted analyzing the efficacy of Lenti-HIV include i) transduction analysis of relevant target cells and organs, ii) expression levels and duration of the immunogen, iii) cellular immune responses to HIV induced in vitro and in vivo, and iv) protection against mucosal infection in a small animal model.

描述（由申请人提供）：最近的研究表明，